Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed at $32.88 in the last session, down -3.61% from day before closing price of $34.11. In other words, the price has decreased by -$3.61 from its previous closing price. On the day, 1.89 million shares were traded. IONS stock price reached its highest trading level at $34.39 during the session, while it also had its lowest trading level at $32.66.
Ratios:
We take a closer look at IONS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.82 and its Current Ratio is at 8.91. In the meantime, Its Debt-to-Equity ratio is 3.00 whereas as Long-Term Debt/Eq ratio is at 2.93.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BMO Capital Markets on August 02, 2024, Downgraded its rating to Market Perform and sets its target price to $60 from $67 previously.
On July 24, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $53 to $62.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 16 ’25 when Swayze Eric sold 7,154 shares for $32.84 per share. The transaction valued at 234,959 led to the insider holds 45,670 shares of the business.
Swayze Eric sold 22 shares of IONS for $719 on Jan 16 ’25. The EVP Research now owns 184 shares after completing the transaction at $32.70 per share. On Jan 16 ’25, another insider, Schneider Eugene, who serves as the EVP, Chf Clinical Develop Ofcr of the company, sold 6,523 shares for $32.79 each. As a result, the insider received 213,889 and left with 58,508 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 5191653376 and an Enterprise Value of 4695477760. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.46 while its Price-to-Book (P/B) ratio in mrq is 7.83. Its current Enterprise Value per Revenue stands at 5.847 whereas that against EBITDA is -13.963.
Stock Price History:
The Beta on a monthly basis for IONS is 0.35, which has changed by -0.35491467 over the last 52 weeks, in comparison to a change of 0.23095727 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $52.49, while it has fallen to a 52-week low of $31.40. The 50-Day Moving Average of the stock is -6.66%, while the 200-Day Moving Average is calculated to be -19.54%.
Shares Statistics:
According to the various share statistics, IONS traded on average about 1.48M shares per day over the past 3-months and 1749680 shares per day over the past 10 days. A total of 157.81M shares are outstanding, with a floating share count of 154.00M. Insiders hold about 2.47% of the company’s shares, while institutions hold 99.36% stake in the company. Shares short for IONS as of 1736899200 were 10239965 with a Short Ratio of 6.91, compared to 1734048000 on 10528956. Therefore, it implies a Short% of Shares Outstanding of 10239965 and a Short% of Float of 7.57.
